Tecentriq (atezolizumab)

€6,298.20
In stock
SKU
Tecentriq (atezolizumab)

How to buy Tecentriq (atezolizumab): You can order Tecentriq (atezolizumab) from TheSocialMedwork if the drug has not been approved or is not available in your country. 

Oncology Urothelial Carcinoma, Lung Cancer
Marketing Authorisation Holder Roche Registration Limited
Mode of Action PD-L1 blocking antibody (immunotherapy)
Administration Intravenous
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Strength 60 milligram / millilitre
Package 1 vial of 20 ml Vials

What is Tecentriq (atezolizumab) for?

Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with:

  • locally advanced or metastatic urothelial carcinoma who have either; disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy1 or are not eligible for cisplatin chemotherapy4.

  • metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy1,5.

How does Tecentriq (atezolizumab) work?

Tecentriq (atezolizumab) belongs to a class of immunotherapy drugs known as checkpoint inhibitors. The drug prevents a protein called PD-L1 that is found on some tumour cells from binding to another protein, PD-1, on immune cells. The binding of these “checkpoint” proteins suppresses the immune response2. Tecentriq (atezolizumab) is a monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors1. By blocking this interaction, checkpoint inhibitors “release the brakes” on the immune system, allowing immune cells to attack tumours2.

Is Tecentriq (atezolizumab) approved?

Tecentriq (atezolizumab) was approved by:

  • Food and Drugs Administration (FDA) (USA)
    • on May 18, 2016, for locally advanced or metastatic urothelial carcinoma, with disease progression on or after prior chemotherapy2. On April 17, 2017, the FDA extended the approval to the use of Tecentriq (atezolizumab) as front-line treatment for advanced or metastatic urothelial carcinoma in patients who are not eligible for cisplatin chemotherapy4.
    • on October 18, 2016, for metastatic non-small cell lung cancer (NSCLC)3.
  • Therapeutic Goods Administration (TGA) (AUS)
    • on July 27, 2017, for metastatic non-small cell lung cancer (NSCLC)5.
  • European Medicines Agency (EMA) (EU)
    • on September 22, 2017, for locally advanced or metastatic non-small cell cancer (NSCLC) and metastatic urothelial carcinoma (mUC) on patients who have been previously treated with a platinum-based chemotherapy and as front-line treatment for advanced or metastatic urothelial carcinoma in patients who are not eligible for cisplatin chemotherapy6.

How do I take Tecentriq (atezolizumab)?

Complete information about Tecentriq (atezolizumab) dosage and administration can be found in the resources section1,5,7. 

The recommended therapy consists of:

  • 1200 mg as an intravenous infusion over 60 minutes every 3 weeks.
  • Dilute prior to intravenous infusion.
Complete information about Tecentriq (atezolizumab) dosage and administration can be found in the resources section. 

Consult your treating doctor for personalised dosing.

Are there any known side effects of Tecentriq (atezolizumab)?

The most common side effects (≥ 20%) in patients with locally advanced or metastatic urothelial carcinoma were fatigue, decreased appetite, nausea, constipation, urinary tract infection, diarrhea, and fever. The most common adverse reactions (≥ 20%) in patients with metastatic non-small cell lung cancer were fatigue, decreased appetite, dyspnea, cough, nausea, musculoskeletal pain, and constipation1
 
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1,5,7.
More Information
Working ingredient Atezolizumab
Shipping method Cold chain (temperature controlled)
Package 1 vial of 20 ml
Therapeutic Area Oncology
Oncology Urothelial Carcinoma, Lung Cancer
Indication Non-Small Cell Lung Cancer (NSCLC)
Indication Locally advanced or metastatic urothelial carcinoma
Administration Intravenous
Mode of Action PD-L1 blocking antibody (immunotherapy)
Strength 60
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Marketing Authorisation Holder Roche Registration Limited
HS Code 30029090
CAS Number 1380723-44-3

The efficacy of Tecentriq (atezolizumab) on urothelial carcinoma was investigated in a study that involved 310 patients with locally advanced or metastatic urothelial carcinoma who had disease progression during or following a platinum-containing chemotherapy regimen or who had disease progression within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant chemotherapy regimen1. Approximately 15% of patients responded to the treatment, and this effect lasted from at least 2.1 months to more than 13.8 months. The most common side effects of treatment with Tecentriq (atezolizumab) were fatigue, decreased appetite, nausea, urinary tract infection, fever, and constipation. The therapy also may cause infection and serious immune system-related side effects2.

The FDA also approved a test, called Ventana PD-L1 (SP142), to measure PD-L1 expression on patients’ tumour-infiltrating immune cells. In the trial, increased PD-L1 expression in patients’ tumours was associated with response to Tecentriq (atezolizumab). Among the trial participants whose tumours were classified as “positive” for PD-L1 expression, 26% experienced a tumour response, compared with 9.5 % of the participants whose tumours were “negative” for PD-L1 expression. However, the result of the test should not be considered as binding as patients whose tumours are classified as negative for PD-L1 expression might still respond to the therapy2.

The approval for the treatment of NSCLC was mainly based on two international, randomised, open-label clinical trials, OAK and POPLAR, that compared Tecentriq (atezolizumab) to docetaxel, a chemotherapy used to treat different types of cancer.

The main efficacy outcome of the study OAK (GO28915) was the overall survival (OS) in a population of 850 patients. The median OS was 13.8 months (95% CI: 11.8, 15.7) in the group treated with Tecentriq (atezolizumab) and 9.6 months (95% CI: 8.6, 11.2) in the group treated with docetaxel. After 18 months 40% of the patients treated with Tecentriq (atezolizumab)were still alive versus 27% of those treated with docetaxel1,5. The main efficacy outcome of the study POLAR (GO28753)  was the OS in a population of 287 patients. The median OS was 12.6 months (95 % CI: 9.7, 16.4) in the group treated with Tecentriq (atezolizumab) and 9.7 months (95% CI: 8.6, 12) in the group treated with docetaxel1,5.
Shipping Type Cold Chain
Shipping method Cold chain (temperature controlled)
This content has been reviewed by our medical doctor Jan de Witt.

How can we help you?

We're ready to answer any question!

Don't speak English? We also speak
Afrikaans, Armenian, Bosnian, Bulgarian, Dutch, German, Italian, Lithuanian, Mandarin, Portuguese, Russian, Serbian, Slovenian, Spanish and Turkish

 

Speak a different language?
Send us a message and we’ll do our best to translate.

 

Our guarantee: We will reply to all messages within 2 hours during office hours.

 

If you want to reach us via phone or chat, please visit our contact page

 

The Social Medwork is registered with the Dutch Ministry of Health in The Hague as an independent intermediary, Registration number 6730 BEM
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.

 

Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card

 

Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.

 

You can order and receive your
medicine in 5 simple steps

1

Talk to your doctor

2

Place order
and send
prescription

3

Pay for order

4

Check documents
for delivery

5

Receive your medicine

Totally awesome!
Keep up the great
work you’re doing!


Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.


learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.